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Drug load in clinical trials: 
A neglected factor
Charles L. P. Deckers, MD, Yechiel A. Hekster, PhD, 
Antoine ICeyser, MD, PhD, Harry Meinardi, M D, PhD, and 
Willy O. Renier, MD, PhD
Nijmegen) The N'etherIcinds
Combinations of drugs are increasingly being 
used on pharmacologic grounds. Examples of the 
use of these combinations include cancer chemo­
therapy treatment and hypertension treatment.1"3 
The goal of using two or more drugs instead of one 
is to achieve greater efficacy with the same or fewer 
adverse effects or equal efficacy with fewer adverse 
effects.4,5 In pharmacologic terms this would signify 
supraadditive efficacy with additive or infraadditive 
toxicity and additive efficacy with infraadditive tox­
icity, respectively. Consequently, numerous clinical 
trials are being undertaken to compare combination 
regimens with their individual constituents.
However, the total drug load (i.e., the amount of 
drug exposure for a certain indication) is a neglected 
factor in many of these trials. When differences in 
effects are found in these trials, they are attributed 
to the pharmacodynamic properties of the therapeu­
tic regimens instead of to a possible difference in 
drug load between the groups. However, the drug 
loads of two regimens should be equal before con­
clusions are reached on differences of intrinsic effi-
cacy or toxicity.
Many examples of neglecting drug load can be 
found in the literature. MacKay et al.6 evaluated 
the effects of 50 mg losartan alone, 12.5 mg hy­
drochlorothiazide alone, a combination of 50 mg 
losartan and 6.25 mg hydrochlorothiazide, and a 
combination of 50 mg losartan and 12.5 mg hy­
drochlorothiazide for essential hypertension and
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concluded that the combination of 50 mg losartan 
and 12.5 mg hydrochlorothiazide produced an ad­
ditive and safe reduction. However, for a clinically 
relevant evaluation they should have included a 
high-dose hydrochlorothiazide group and a high- 
dose losartan group, or they should have used 
lower doses of both drugs in the combination 
regimen (i.e., to compare regimens with a more 
equal drug load). This would have challenged the 
merits of the combination of losartan and low- 
dose hydrochlorothiazide. Similarly, studies by 
Faarvang et al.7 on the possible advantages of 
combining antirheumatic drugs and by Nelson et 
al.8 on the possible advantages of combining an- 
tidepressive drugs also did not include high-dose 
monotherapy groups or lower dosages for the 
combinations.
Another frequently encountered manner in which 
drug load is neglected is the habit of not taking 
baseline medication into account. Onghena and van 
Houdenhove9 reviewed 39 placebo-controlled trials 
on antidepressant-induced analgesia for chronic 
nonmalignant pain and found that the use of other 
analgesic agents, ergotamine, or antirheumatic 
drugs was permitted in these trials. For example, in 
one of the reviewed articles, a study by Loldrup et 
al.,10 patients were allowed to have up to 30 mg 
oxazepam and up to 3 gm acetaminophen (INN, 
paracetamol) in addition to the study medication, 
without taking between-group differences of oxaze­
pam and acetaminophen into account. In an antihy­
pertension drug trial research, Avanzini et al.11 com­
pared the effects of four different drug regimens, but 
one regimen began with a considerably higher drug 
load than the others.
This problem is also important in add-on studies 
of antiepileptic drugs. The first trials to establish 
efficacy of a new antiepileptic drug are conducted by 
comparison of the new drug plus the existing, insuf­
ficiently effective, medication to placebo plus the
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existing medication. This is necessary because it is 
unethical to give only new antiepileptic drugs or 
placebo to patients with newly diagnosed epilepsy; 
thus the effects of the new compound are evaluated 
as though only the new drug were given. Plowever, 
we found that the total drug loads of baseline med­
ication of the active and placebo groups sometimes 
differ, and therefore it is unclear whether observed 
differences in toxicity are really the result of the new 
antiepileptic drug or whether they are related to 
drug load.12
Polytherapy is being avoided in epilepsy treat­
ment because of the fear of adverse effects. This is 
based on studies published around 1980 in which 
patients who were switched back from polytherapy 
to monotherapy experienced a decrease in toxicity. 
However, the patients in these studies had not only 
a reduction in the number of antiepileptic drugs but 
also in drug load.12 Comparison of toxicity between 
patients receiving monotherapy and patients receiv­
ing polytherapy with equal drug loads has shown 
that toxicity does in fact not differ between these 
groups.13
Although the concept of drug load is intuitively 
obvious, little has been published about a method 
to evaluate drug load in polytherapy. Such a 
method should be helpful in the planning and 
analysis of clinical trials and should enable deter­
mination of the role of drug load as a prognostic 
factor. In experimental settings, fractions of drug 
exposure are already used in the isobole method, 
This is the preferred method to detect synergy, 
zero interaction, or antagonism.14 The dosages of 
a drug combination (du, db ) are determined that 
have the same effect as certain dosages of the 
drugs alone (Da and Db). The equation for the 
zero interaction line for two agents is as follows; 
da/Da -I- db/Db ™ l . i4,us When the sum is less than 
one, the combination is judged to be supraaddi- 
live; when the sum is more than one, the combi­
nation is judged to be infraadditive. The interac­
tion can thus be evaluated for the dosages used, 
irrespective of the dose-response curves of the 
individual drugs. We have developed a method to 
assess drug load that is analogous to the isobole 
method.
Methods
The unity of drug load can be defined as the 
average amount of drug needed to obtain the de­
sired effect in the general population. To approxi­
mate the unity drug load, the defined daily dose as
Table I. Defined daily dose values of 
antiepileptic drugs as assigned by the World 
Health Organization (1996)















published by the World Health Organization may be 
used,*
The defined daily dose was introduced by the 
World Health Organization Drug Utilization Re­
search Group as a tool to convert drug consumption 
data from different sources into comparable units.16 
The World Health Organization Group determines 
and assigns the average maintenance dose of a drug 
for its main indication—the defined daily dose—for 
each individual drug by analysis of literature and 
drug registration data. The defined daily dose values 
of antiepileptic drugs are listed in Table I. The 
prescribed daily dose is the average prescribed dose 
in a particular population.
The prescribed daily dose/defined daily dose ratio 
can be used to calculate the drug load in treatment 
groups when the prescribed daily dose is used as the 
average dose of a drug taken in a certain treatment 
group. The method assumes that, thus normalized, 
the loads of several drugs in one regimen may be 
added.
For example, the defined daily dose of valproate 
sodium is 1500 mg and patients in group A taking 
900 mg valproate would have a drug load of 900/ 
1500, that is, 0.6 prescribed daily dose/defined daily 
dose. The defined daily dose of carbamazepine is
1000 mg and patients in group B taking 600 mg 
carbamazepine would have a drug load of 600/1000, 
which is also 0.6 prescribed daily dose/defined daily 
dose. Patients in group C taking 450 mg valproate 
and 300 mg carbamazepine would have an equal 
total drug load of 0,6 prescribed daily dose/deiined
daily dose, which makes them eligible for compari­
son with patients of groups A and B.
■"For information on iussigned defined daily dose values, contact 
the World Health Organization Collaborating Centre for Drug 
Statistics Methodology» c/o Norsk Medisinaklepol AS, PC Box 
100, Veitvet, N-0158 Oslo, Norway (phone: 47-22169810; to: 
47-22169818),
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Results in epilepsy research
We have applied the described method of mea­
suring drug loads in a retrospective analysis of anti- 
epileptic drug trials in which multiple drug regimens 
were used. In this review, toxicity was weakly but 
significantly correlated with drug load and not with 
the number of antiepileptic drugs.12 In one of the 
trials we analyzed, the authors assessed the neuro­
psychologic effects of a fixed dose of the antiepilep­
tic drug vigabatrin in an add-on placebo-controlled 
paradigm.17 No differences in neuropsychologie ef­
fects were found, and it was concluded that vigaba­
trin did not have a large effect on cognitive func­
tioning. However, analysis of the total drug loads of 
the two treatment groups revealed that, notwith­
standing the addition of vigabatrin to one group, 
drug loads in both treatment groups differed only 
slightly.12 This greatly decreases the likelihood of 
finding any difference in effect, if mechanisms are 
similar.
We have also used the prescribed daily dose/ 
defined daily dose ratio to start patients off with 
equal drug loads in both treatment groups of a 
clinical trial. In a recently initiated trial, we are 
comparing carbamazepine monotherapy to a com­
bination of carbamazepine and valproate sodium 
and all patients start with a drug load of 0.4 
prescribed daily dose/defined daily dose, whether 
receiving monotherapy or duotherapy. This pre­
vents bias; for example, when one treatment 
group starts with a lower drug load it may take 
longer to get these patients into remission, al­
though the drugs may be equally effective. A lter­
natively, in a treatment group that starts off with a 
higher drug load, more patients may drop out fast 
because of adverse effects, while in fact the two 
regimens may be equally toxic when equal drug 
loads are used. Furthermore, the prescribed daily 
dose/defined daily dose ratio allows physicians 
participating in this trial to adjust the dose in 
terms of prescribed daily dose/defined daily dose, 
thus keeping physicians, patients, and investiga­
tors blinded.
In addition, prediction of the outcome of drug 
withdrawal after a reasonable symptom-free pe­
riod may benefit from the concept of drug load. 
Until now, the number of antiepileptic drugs has 
been deemed to be an important factor in deter­
mining the risk of seizure recurrence,18 The total 
drug load of the antiepileptic drug regimen may 
very well prove to be of more relevance in this 
respect.
Discussion
Failure to evaluate drug load may complicate the 
evaluation of drug efficacy and toxicity, especially 
where combination therapy or fixed dosages are 
concerned. Equal drug loads should be verified at 
the start of treatment, as well as determined in the 
retrospective analysis of clinical trials. In our field 
antiepileptic drug treatment—neglecting drug load 
obscures the evaluation of new antiepileptic drugs 
and has also unjustly caused polytherapy to be 
blamed for increased toxicity.
With use of the prescribed daily dose/defined 
daily dose ratio, it is possible to evaluate whether an 
equal load of polytherapy may offer advantages 
compared with conventional monotherapy. Obvi­
ously, the inherent assumption when using this 
method is that the combination will exhibit additive 
activity. Deviations then will provide information 
about infraadditive or supraadditive activity. An­
other assumption is that the defined daily doses 
published by the World Health Organization are 
equipotent.
Conclusion
Drug load is a neglected factor in many trials in 
which drug combinations or fixed dosages are used. 
Taking drug load into account will clarify the inter­
pretation of the results of these trials. As a crude 
indicator the prescribed daily dose/defined daily 
dose ratio has already been useful to us in the 
assessment and planning of antiepileptic drug trials.
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